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Abstract 32 
Orally dispersing tablets (ODTs), also known as orodispersibles, were first introduced into the market in 33 
1980s to overcome dysphagia problems amongst paediatrics and geriatrics.  Despite their abilities to avoid 34 
swallowing difficulties, frequency of dosing stood as a barrier for these formulations. The aim of the current 35 
study is to produce and optimize a sustained release orally disintegrating tablets (SR-ODT), with the aid of 36 
chitosan. A design of experiment (DoE) was first performed using Minitab to determine the effect of five 37 
independent variables on three dependent responses when producing the nanoparticles using ionotopic 38 
gelation. The variables studied were (tripolyphosphate concentration TPP, Chitosan concentration CS, acetic 39 
acid concentration, Chitosan: tripolyphosphate ratios and stirring time) and the responses were (particle 40 
size, surface charge and encapsulation efficiency). A formulation with optimum particle size, surface charge 41 
and encapsulation efficiency was prepared and further coated with polyvinylpyrolidine (PVP), polyethylene 42 
glycol (PEG) and polyethylene co-acrylic acid (PEAA). Minitab studies revealed that the nanoparticles’ particle 43 
size was affected by most of the independent variables except stirring time and the ratios of CS to TPP. The 44 
optimized nanoparticles showed particle size of 153.8±14 nm, surface charge of 31.4±0.9 mV and 45 
encapsulation efficiency of 99.7±0.06%. The DSC showed that PMZ was solubilized within chitosan 46 
nanoparticle, whereas SEM images indicated that all the samples were spherical in shape with smooth 47 
surface and had similar size to that measured by DLS. After coating and dispersing into the tablets’ matrices, 48 
the tablets were evaluated to determine the friability, disintegration time and tensile strength. All tablets 49 
were at an appropriate friability (less than 1%) and had tensile strength above 2.5 N/mm2. Besides, all the 50 
tablets managed to disintegrate within 40 seconds while sustaining the drug release over 24 hours.  51 
Keywords:- orally disintegrating tablets, chitosan, design of experiment, sustained release, polymers. 52 
1.Introduction 53 
 54 
Oral drug delivery is the most common route of drug administration and the last 10 years have witnessed 55 
significant developments in oral formulations as novel dosage forms and manufacture technologies have 56 
been introduced. A new dosage form known as orally dispersing tablets (ODTs) was introduced in 1980s to 57 
overcome a common clinical problem known as dysphagia among paediatric and geriatric populations. The 58 
clinical study conducted by Lindgren and Janzon (1991) showed that 35% of patients aged between 50 and 59 
69 suffered from some degree of dysphagia. It has also been established that nearly 1 in 5 patients avoid 60 
taking oral medication due to swallowing difficulties (Lindgren & Janzon, 1991; Krause & Breitkreutz, 2008). 61 
Dysphagia is also associated with poor patient compliance, the latter is a foremost medical issue that costs 62 
more than $290 billion a year (Fulzele, Moe & Hamed, 2012.; Gryczke, Schminke, Maniruzzaman, Beck, & 63 
Douroumis, 2011).Therefore, the need for a viable oral disintegrating formulation is paramount. ODTs are 64 
also termed as orodispersible in the European Pharmacopoeia and defined as ‘tablets that disperse or 65 
disintegrate in less than 3 mins in oral cavity before it is turned into a paste that can be easily swallowed 66 
(Hirani, Rathod, & Vadalia, 2009; Beckert, Lehmann, and Schmidt, 1996; Wagh, Kothawade, Salunkhe, 67 
Chavan, & Daga. 2011)  68 
The first generation of ODTs achieved a lot of success, with various properties and characteristics of ODTs 69 
offered by the numerous preparation techniques.  Nonetheless, the first generation of ODTs failed to 70 
overcome challenges such as delivering acid labile drugs, macromolecule and high doses. A lot of studies 71 
investigated new approaches to circumvent these technical issues. Further research into ODTs resulted in 72 
the production of sustained-release oral disintegrating tablet (SR-ODT) with the aim of improving the oral 73 
disintegrating drug delivery system. This is where the tablet disintegrates completely in the mouth but also 74 
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sustain the duration of action. This will reduce the frequency of dosing and will enhance patient adherence 75 
to ultimately improve the quality of lifestyle for patients (Abdul & Poddar. 2004). Many approaches such as 76 
microencapsulation (Sunitha, & Amareshwar. 2010; Shazly, Tawfeek, Ibrahim, Auda, & El-Mahdy, 2013), 77 
nanoparticles (Kondo, Ito, Niwa, & Danjo, 2013) ion exchange resins (Chen et al., 1992; Gokhale and 78 
Sundararajan., 2013) and stimuli-responsive polymers (Beckert, Lehmann, and Schmidt 1996; Abbaspour,  79 
Sadeghi & Garekani,  2008) have been adapted to control the drug release across ODTs. 80 
Recently, chitosan (CS) has attracted great attention in pharmaceutical industry to produce sustained release 81 
delivery systems, due to its biodegradability and biocompatibility, in addition to, its nontoxicity (Jiang, Pan, 82 
Cao, Jiang,  Hua, & Zhu, 2012).  Chitosan is considered as one of the most abundant natural polysaccharide 83 
(Jiang, Pan, Cao, Hua, &Zhu, X.2012; Bugnicourt, Alcouffe, & Ladavière. 2014) which is chemically known as a 84 
β-(1,4)-2-acetamido-D-glucose and β-(1,4)-2-amino- D-glucose and comprises of of glucosamine 85 
copolymerised with N-acetyl glcosamine (Kaloti, & Bohidar 2010), the primary amino group and two free 86 
hydroxyl groups on carbon (C8) provides a positive charge on the surface (Fig 1A) .CS has a pka of 6.3-7 and is 87 
only soluble in aqueous media at low pH, which might lead to a premature release of the drug.  88 
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Fig 1:- Chemical structure of chitosan (A) and promethazine (B). 90 
 91 
Chitosan is considered to be safe, as low molecular weight chitosans are eliminated easily by the kidney, 92 
while, the larger molecular weight polymers are degraded by chemical and enzymatic catalysis, furthermore 93 
the enzyme catalysis is dependent on the availability of chitosan amino group. The ability of CS to form nano-94 
microparticulate systems depends on its ability to form covalent cross-linking between the chitosan chain 95 
and the functional cross-linking agent such as polyehtlene glycol (PEG), dicarboxlylic acid or 96 
tripolyphosphate. Patel et al (2013) utilised CS to develop a sustained delivery system of Rifampicin. 97 
Rifampicin nanoparticles were prepared by ionic gelation method in presence of tween-80 and 98 
tripolyphosphate to act as surfactant and cross-linker respectively. The prepared nanopartiuculate system 99 
had particle sizes of 181nm – 383nm and managed to sustain rifampicin release for 28-34 hours. It was 100 
further concluded that extensively cross-linked nanoparticles displayed decreased drug release rates (Patel, 101 
Parikh, & Aboti, 2013). Li-Q et al attempted a new microencapsulation technique to produce a SR ODT for 102 
scopolamine hydrobromide, where the nanoparticles are encapsulated to produce a sustained-release 103 
effect. The particles were produced using ionotropic gelation followed by spray drying, in vitro studies 104 
showed that tablets have disintegration time of <45s, particle size of 300 nm and managed to release 90% of 105 
the drug within 90min (Li, , et al., 2011). Other studies demonstrated that CS alone might not be able to 106 
A 
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sustain the drug release. Abdelbary et al conducted in vitro and in vivo evaluation of microencapsulated 107 
glipizide for orally extended delivery. After preparing glipizide microcapsules by ionotropic gelation 108 
technique, the microcapsules were coated with alginate alone or combined with carbomer 934P. It was 109 
concluded that the extended release of drug depended on the composition of the outer coat. Microparticles 110 
coated with sodium alginate alone or in combination with low molecular weight (LMW) chitosan were found 111 
to be unsuccessful at retarding the drug release. However, when LMW chitosan was replaced by high 112 
molecular weight chitosan, approximately 80% of the drug was released after 8 hours. Other polymers were 113 
employed in preparing sustained release particulate systems across ODTs. The production of ketoprofen 114 
controlled release ODT was investigated using Eudragit RS-30D. The pellets were directly compressed and 115 
the in vitro studies revealed disintegration time of 30s.  (Wei, Yang, & Luan, 2013). 116 
Promethazine (PMZ) is the model drug used in this study (Figure 1B); pharmacologically PMZ is used as a H1 117 
and alpha-adrenergic receptor antagonist, with a limited effect on dopaminergic receptor. PMZ is used 118 
widely to treat allergy symptoms such as itching, runny nose, sneezing, itchy or watery eyes, hives, and itchy 119 
skin rashes (Kavanagh, Grant et al. 2012). PMZ also prevents motion sickness and treats nausea, vomiting 120 
and pain after surgery. Furthermore, PMZ is used as a sedative or sleep aid (Ford, Rubinstein et al. 1985). 121 
Pfeil and colleagues have found that PMZ is considered as the mostly prescribed antiemetic in the US, as 122 
more than 90% of the prescriptions for antiemetic’s are promethazine  in comparison to other antiemetic on 123 
the market (Adolph, et al., 2012) 124 
Due to the wide interest and promising results obtained when using chitosan to produce a sustained-release 125 
nanoparticles the aim of this study is to produce a sustained release nanoparticle system, to be integrated 126 
into an oral disintegrating tablet matrix. The study also aims to compare the effect of different coating 127 
polymers on the drug release profiles of PMZ and their toxicity on Caco-2 cells. 128 
2. Material and method  129 
2.1. Material 130 
Promethazine hydrochloride (MW 320.88) was purchased from Tokyo chemical industry co, (Tokoyo,Japan). 131 
Chitosan (CS) of medium molecular weight (MW, 190,000-310,000 Da) and with degree of  deacetylation 132 
(DD) of 75%, Sodium tripolyphosphate (TPP), Polyethylene glycol PEG (Mn 80,000 units), 133 
Polyvinylpyrrolidone (PVP), Poly ethylene co acrylic acid, Magnesium stearate fluka (analytical standard 134 
≥99.5%) and D (+)-Lactose Monohydrate were all purchased from Sigma-Aldrich (Mo, USA), L-substituted 135 
hydroxypropylcellulose; LH-B1 -MW, 140,000 Da, 11% hydroxypropoxy content, degree of polymerization of 136 
790 and 0.2 molar substitution- was a gift from Shin-Etsu Chemical co.td. (Tokyo, Japan).  137 
The Caco-2 cell lines were obtained from Sigma Aldrich (Dorset, UK), while Essential Eagle’s Medium (EMEM) 138 
L-glutamine,  fetal bovine serum Penicillin Streptomycin were all purchased from Fisher Scientific 139 
(Loughborough, UK). 140 
2.2 Methods 141 
2.2.1. Design of experiment (DoE) 142 
 143 
A factorial design of experiment was used to determine the effect of six dependent variables on three 144 
responses and to optimize the experiment conditions to achieve a nanoparticulate system with small particle 145 
size (100-300nm) with maximum drug loading. A fractional factorial design was generated where the 146 
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variables used in this design were CS concentration (0.1-0.5% w/v), TPP concentration (0.1-.05% w/v), acetic 147 
acid concentration(0.5-1% v/v), CS:TPP (5:1- 5:2) ratio and drug concentration(0.4-0.8 mg/mL) and stirring 148 
time (30- 90 mins) while the responses were particle size, surface charge and drug loading. A total of 16 149 
experiments were performed in order to optimise the properties of nanoparticles produced (Table 1). In 150 
order to minimise the effect of extraneous factors on actual responses, the experimental runs were 151 
randomized. The response surface model was evaluated using equation (1) where Y is the response value 152 
predicted by the model of which α0 is a constant whereas αi , αij, αijh are linear, 2-way and 3-way interaction 153 
coefficient respectively. A response optimizer was used to obtain optimum conditions to produce 154 
nanoparticles in the size range of (100-250nm) and maximum drug load. The experimental design and data 155 
analysis were carried out using Minitab statistical package (Minitab® 17.1.0, Minitab inc., PA, USA) 156 
Y= α0+∑ αiXi+∑ αij Xij+∑ αijh Xijh Equation 1 157 
Table 1:- Matrix of 16 runs used to optimise chitosan nanoparticles 158 
  159 
2.2.2. Preparation of CS/TPP nanoparticles 160 
CS/TPP nanoparticles, were prepared using ionotropic gelation method (Calvo, Remunan, Vila, & Alonso, 161 
,1997) CS solution was prepared in concentrations of (0.1%-0.5%w/v) in acetic acid solution (0.5%-1% v/v). A 162 
Second solution of TPP was prepared at concentration of (0.1%-0.5%w/v) in deionized water. After filtration 163 
using 0.24µm syringe filters (Millex®-HA,Merck KGaA, Germany), TPP was added to CS solution dropwise 164 
until ratios of (5:1 and 5:2) were achieved. The obtained CS:TPP solutions were stirred under ambient 165 
conditions for (30-90 mins), which led to spontaneous formation of nanoparticles. The nanoparticles were 166 
obtained by centrifugation of the sample at 20.000 rmp for 30min at temperature of 4oC using (SIGMA  3-167 
30K, SciQuip, Germany) and the pellets obtained were washed by dispersing the pellets in distilled water and 168 
centrifugation for 15min. (Calvo, Remunan, Vila, & Alonso, ,1997;  Najafabadi, Abdouss, & Faghihi, 2014; 169 
Makhija, & Vavia 2002)  170 
Number 
of runs 
CS-conc 
(%w/v) 
TPP-conc 
(%w/v) 
CS:TPP 
ratio 
Stirring time 
(min) 
drug concentration 
(mg/ml) 
acetic acid 
(%v/v) 
1 0.5 0.1 5:2 30 0.4 0.5 
2 0.1 0.1 5:1 30 0.4 1.0 
3 0.1 0.5 5:2 30 0.4 1.0 
4 0.1 0.1 5:2 30 0.8 0.5 
5 0.1 0.5 5:2 90 0.4 0.5 
6 0.1 0.1 5:1 90 0.4 0.5 
7 0.1 0.5 5:1 90 0.8 1.0 
8 0.1 0.1 5:2 90 0.8 1.0 
9 0.5 0.5 5:1 30 0.4 0.5 
10 0.5 0.1 5:1 30 0.8 1.0 
11 0.1 0.5 5:1 90 0.8 0.5 
12 0.5 0.1 5:1 90 0.8 0.5 
13 0.5 0.5 5:2 90 0.8 0.5 
14 0.5 0.5 5:2 30 0.8 0.1 
15 0.5 0.5 5:1 90 0.4 0.1 
16 0.5 0.1 5:2 90 0.8 0.1 
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PMZ nanoparticles were prepared using similar method. Where the drug (PMZ) was added in concentration 171 
of (0.4-0.8mg/mL) to the CS solution under magnetic stirring for 30min (Calvo, Remunan, Vila, & Alonso, 172 
,1997;  Najafabadi, Abdouss, & Faghihi, 2014; Makhija, & Vavia 2002) before adding TPP solution. 173 
2.2.3. Preparation of CS and PMZ coated nanoparticles 174 
After optimizing CS nanoparticles, the obtained particles were further coated using three polymers namely; 175 
PEG, PVP and PEAA to sustain the drug release across the nanoparticulate system. CS/TPP coated 176 
nanoparticles were prepared by adding the polymer in concentration of (10-20mg/ml) to the CS/PMZ 177 
solution prior to initiating the ionic gelation by adding TPP.  178 
 179 
2.2.4. Tablet formulation 180 
The prepared nanoparticles were embedded inside orally disintegrating tablet matrix made of 25% LH-B1, 181 
1% lubricant (Magnesium stearate), nanoparticles contacting 5% drug (10mg or equivalent of PMZ) and 69% 182 
diluent (D (+)-Lactose Monohydrate), all ingredients were mixed using (WAB Turbula®,willy A,Bachofen AG, 183 
Switzerland) and compressed using uniaxial hydraulic press (Specac tablet presser, Slough, UK) and split die 184 
which prevents mechanical failure by allowing triaxial decompression. The prepared tablets were cylindrical 185 
with a diameter of 13 mm and weight of around 500 mg. Tablets were left in desiccators until 186 
characterisation studies were performed.  187 
2.2.5. HPLC Analysis 188 
PMZ analysis was performed using (Shimadzu, Shimadzu Corporation, Japan) HPLC system. RP-C18 column 189 
(250x4.6 mm, 5µm) was used to retain PMZ using mobile phase made of acetonitrile and 0.354%v/v 190 
triethylamine solution (pH of 2.5 adjusted with orthophosphoric acid), in a ratio of 41:59 (v/v) respectively. 191 
Mobile phase was pumped using a quaternary pump at a flow rate of 1ml/min. PMZ had retention time of 192 
2.36±0.01 mins when analysed at λmax of 250 nm. The analytical method was validated according to 193 
International Conference of Harmonization (ICH) guidelines. Calibration curve was established at 194 
concentrations ranges of 10-200µm with coefficient of variation (R2=0.99) and curve equation (y = 56839x + 195 
106).  196 
2.2.6. Nanoparticles characterisation 197 
2.2.6.1. Dynamic light scattering transmission:  198 
Particle size distribution, polydispersion and zeta potential (ξ) of the nanoparticles were analysed through 199 
DLS, the analyses were performed using diluted suspension of nanoparticles at 1:10 v/v dilution using  200 
Malvern Zetasizer 300HSA (Malvern Instruments, UK) fitted with a detector at angle of 90° . All the analysis 201 
were carried out at room temperature and expressed as mean±SD of three readings. Zeta potential (ξ) was 202 
measured in triplicates by photon correlation spectroscopy (PCS) using Malvern Zetasizer 300HSA (Malvern 203 
Instruments, UK).  204 
2.2.6.2. Thermogravimetric analysis (TGA) 205 
A thermogravimetric analyser (Toledo SDTA/TGA 851e, UK) was used in this study to measure the moisture 206 
content and decomposition temperature of PMZ and its prepared nanoparticles. 5- 10 mg of samples were 207 
loaded on to an open pan and were analysed between 20-500 oC at 10 oC/min scanning rate and under 208 
nitrogen stream. Software (STAReSW 10.00) was used to analyse the obtained thermograms. 209 
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2.2.6.3. Differential scanning calorimetry (DSC). 210 
Differential scanning calorimeter (Mettler Toledo, DSC822e, UK) was used to explore the physical 211 
transformation of PMZ and the prepared nanoparticles by determining the heat flow from and to the 212 
sample. Approximately 2-5 mg of the samples were weighted and transferred to an aluminum sample pan 213 
(50 µL capacity). Intra cooler 2P system was used to initially cool the samples to 25 oC and then sample 214 
heated to 250 oC at a rate of 10 oC/min. Nitrogen was used as a purge gas at a flow rate of 20 mL/min. The 215 
obtained thermograms were analysed using STAReSW 10.00 software. All experiments were performed in 216 
triplicate and an empty aluminum pan was used as a reference cell for all the measurements. Both sample 217 
and reference pans were covered by aluminum lids and pierced on the top. 218 
 219 
2.2.6.4. Scanning electron microscopy (SEM) 220 
Scanning electron microscopy (SEM, Zeiss Evo50- Oxford instrument, UK) was used to study the surface 221 
morphology of PMZ and the prepared nanoparticles. Samples were prepared by sprinkling PMZ or adding a 222 
drop of nanoparticles suspension onto specimen stubs. After drying the suspension, stubs were loaded onto 223 
a universal specimen holder. In order to enable electricity conduction, samples were coated with a fine layer 224 
of gold using a sputter coater (Polaron SC500, Polaron Equipment, Watford, UK) at 20 mA for three mins at 225 
low vacuum and in the presence of argon gas (Polaron Equipment, Watford, UK). 226 
2.2.6.5. Determination of encapsulation efficiency of nanoparticles using HPLC. 227 
HPLC method (section 2.2.5) was used to determine the percentage of encapsulation efficiency in the 228 
prepared nanoparticles. In this process, the supernatant of the nanoparticle that was collected during 229 
centrifugation was filtered and analysed using HPLC and equation (2) was used to calculate % PMZ 230 
encapsulation efficiency.  231 
%𝐷𝑟𝑢𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =
 𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔−𝑓𝑟𝑒𝑒 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔
𝑥100   Equation 2 232 
2.2.6.6. Sulforhodamine B (SRB) cytotoxic assay.  233 
2.2.6.6.1 Caco-2 cells culture 234 
The Caco-2 cell line was grown in Minimum Essential Eagle’s Medium (EMEM) that was supplemented with 235 
200 mM L-glutamine,  10% fetal bovine serum, 10,000 U of Penicillin and 10 mg/mL of Streptomycin.  Caco-2 236 
cells were maintained in humidified atmosphere of 5% ±0.5 CO2 and at a temperature of 37 ±0.5 ºC. All 237 
experiments were preformed between passages 57-60.  238 
2.2.6.6.2 Sulforhodamine B (SRB) cytotoxic assay 239 
Cytotoxic effect of the prepared nanoparticles was evaluated using Sulforhodamine B (SRB). SRB protocol 240 
was adapted from Vichai and Kirtikara (2006). Briefly, Caco-2 cells were seeded in a 96 well plate at a density 241 
of 20,000 cell/well. The cells were incubated for 24 hours at a temperature of 37 ±0.5 ºC and humidified 242 
atmosphere of 5% ±0.5 CO2. The nanoparticles were centrifuged, and the supernatant discarded, the 243 
nanoparticles were re-suspended in the treatment media prior the test. The cytotoxic assay was evaluated 244 
for the following concentration of 40 mg/mL, 20 mg/mL and 10 mg/mL of nanoparticles suspension.  After 245 
the 24 hours cultured period, the cell media was removed and 100 µL of the test materials were added. The 246 
test materials used were: nanoparticles (different concentration) suspension, the negative control 247 
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(treatment media only) and positive control (50µm trytona X). This followed by another 24 hours incubation 248 
time using the same condition above. After the second incubation, the cells were fixed by treatment with 249 
100 µL of 10% Trichloroacetic acid (TCA) for 1 hour. Then, the TCA was washed out thoroughly with water 250 
and left to dry overnight.  SRB dye was added to each well (100 µL of 0.4% SRB) for 30 mins then washed out 251 
using 1% acetic acid and the plate was kept for drying overnight. The SRB dye was de-stained using 100 µL 252 
tris buffer and the optical density was measured at 565 nm using Epoch Spectrophotometer (Bio TeK, VT, 253 
USA). 254 
 255 
2.2.7. Tablet evaluation 256 
2.2.7.1. Measurement of tablet tensile strength 257 
The force required to crush the prepared tablets was measured using tablet hardness apparatus (Schleungier 258 
4M, Thun, Switzerland). The measured force was used to determine the tablet tensile strength using 259 
equation (2) (Digital Vernier Dial Caliper Gauge Micro Meter 150mm(UK). 260 
dt
Fc


2
   Equation 3 261 
Where σ is the tablet tensile strength, Fc is the crushing force required to break the tablet, d is the tablet 262 
diameter and t is the tablet thickness. All measurements were done in triplicate. 263 
2.2.7.2. Measurement of tablet disintegration time  264 
Disintegration time is the time required for tablets to disintegrate completely without leaving any solid 265 
residue. In vitro disintegration time was evaluated using US pharmacopoeia monograph (<701> 266 
disintegration). Erweka ZT3, Appartebau, GMBH ,Husenstamm, Germany) was used in this study as a 267 
disintegration apparatus and distilled water (800 ml) as disintegration medium; the disintegration medium 268 
temperature was maintained at 37±0.5 °C by thermostat. Six tablets were placed in the basket rack 269 
assembly and covered by transparent plastic disks. The disintegration time was taken as the time required 270 
for tablets to disintegrate completely without leaving any solid residue. All the measurements were carried 271 
out six times and presented as mean ± standard deviation. 272 
 273 
2.2.7.3. Measurement of friability  274 
The friability will be determined as a percentage of weight loss in a random sample of tablets. A random 275 
sample of tablets will be weighed on an analytical balance to achieve a total mass weight of (>5g), based on 276 
the British pharmacopoeia guidelines for friability testing. Then tablets were placed in a friabilator (Erweka 277 
AR 400 ,Germany) for 4 min at 25rmp, after that the tablets were dusted and reweighed. Percentage 278 
friability will be calculated using equation (3)  279 
% 𝑓𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡−𝑓𝑖𝑛𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
∗ 100   Equation 4 280 
2.2.7.4. Dissolution test (Drug release) 281 
The dissolution of ODTs tablets containing 10 mg of PMZ or equivalent amount of PMZ nanoparticles was 282 
evaluated using USP II paddle method (Caleva 9ST, Germany). The prepared tablets were placed into 283 
dissolution vessels containing 900 mL of 0.01M HCL buffer (pH 1.2) and the dissolution media was 284 
maintained at 37oC±0.5oC and stirred at 50 rpm. 5mL of samples were collected at a predetermined time 285 
intervals (5min,10min, 15min, 20min, 30min, 60min, 90min, 120min, 6hr, 22hr, 24hr) then filtered through 286 
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0.45 μm Millipore filters. The dissolution media was replaced by 5mL of fresh dissolution media in order to 287 
maintain a constant volume. After proper dilution samples were analysed by HPLC method (section 2.2.5). 288 
2.2.7.5. Statistical analysis  289 
Formulation were prepared and analysed in triplicate and the results were expressed as ± mean standard 290 
deviation.  Graph pad Prism® 6 (version 6.5) was used to analyse the date obtained, the results were 291 
analysed by two-way ANOVA (Tukey) p<0.05 was considered to be statistically significant for this analysis.  292 
  293 
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3. Results and discussion  294 
 295 
3.1. Design of experiment (DoE) 296 
 297 
 Two-level factorial design of experiment was performed, with the use of six parameters (CS concentration, 298 
TPP concentration, acetic acid concentration, stirring time and CS:TPP ratio), where Minitab generated 16 299 
experiments, that were produced and evaluated based on the three variables; particle size, surface charge (ξ) 300 
(Fig 2) and encapsulation efficiency (EE). The DoE approach was employed in order to optimize the 301 
experiment conditions and produce a sample with the desired properties, a small particle size (100-300nm) 302 
and high encapsulation efficiency. High encapsulation efficiency means use of fewer amounts of 303 
nanoparticles, hence tablet characteristics would not be compromised especially disintegration time. In 304 
other words, poor entrapment efficiency would require high amounts of the polymeric nanoparticles which 305 
would bind strongly to other excipients in the tablet matrix and tablet disintegration would fail.  After 306 
evaluation of all samples, the date was uploaded into Minitab, to statistically analyses the data obtained, 307 
Minitab generated a number of graphs to show the impact of each variable on the responses. 308 
 309 
 310 
Fig 2:- Summary of the effect of various variables on the particle size and surface charge 311 
3.1.1. The effect of different parameters on particle size  312 
 313 
Particle size is an important determinant of drug bioavailability as it is believed that nanoparticles with size 314 
less than 100 nm has 3-fold arterial uptake compared to larger particles (Song, Labhasetwar, Cui, 315 
Underwood, & Levy, 1998). From formulation aspect, particles with smaller size will have a larger surface 316 
area and increasing the surface area will enhance the ability of the particles to withstand the compression 317 
0
10
20
30
40
50
60
70
80
0
500
1000
1500
2000
2500
3000
3500
4000
4500
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Su
rf
ac
e
 c
h
ar
ge
 (
m
V
) 
P
ar
ti
cl
e
 s
iz
e
 (
n
m
) 
Experimental runs 
Particle size Surface charge
11 
 
force during the tableting process by decreasing the overall compression pressure per particle, hence 318 
optimising the particle size is a mandate in the current study.  Formation of CS nanoparticles depends on the 319 
ability of the polymer to form intermolecular cross-linkages with polyanions such as TPP.  The extent of 320 
Intermolecular cross-linkages between the phosphate groups of TPP and the amino groups of CS will control 321 
and modulate the properties of CS nanoparticles prepared.  The current study looked at the effect of six 322 
independent variables on the size of CS particulate system.  The DoE study demonstrated that particle size is 323 
dramatically influenced by most of the variables; CS concentration, acetic acid concentrations, drug 324 
concentrations and TPP concentrations. On the other hand, stirring time and CS:TPP ration did not show any 325 
impact on the size of CS nanoparticles (Figs 3 &4). 326 
 327 
Fig 3:- Main effects plot showing the influence of the independent variables on CS particle size 328 
12 
 
 329 
Fig 4:-Response surface plots of interaction effects between different variables and their effect on CS particle 330 
size. Hold values are 0.20 for CS, 0.30 for TPP, 1.50 for CS:TPP, 60.00 for ST, 0.45 for DC and 0.30 for AA. 331 
According to the main effect plot (Fig 3), CS concentrations had the foremost influence on the particles size 332 
of the prepared nanoparticles.  Increasing CS concentration was associated with an increase in the average 333 
particle size of the nanoparticles. Possibly increasing the concentration of CS results in a viscosity 334 
increase,  which in turn will affect the shear capacity of homogenization leading to the formation of 335 
aggregates with larger particle size (Hong et al., 2014; Bugnicourt, Alcouffe, & Ladavière. 2014). Similar 336 
findings were also reported by Bugnicourt et al., 2014 (Bugnicourt, Alcouffe, & Ladavière. 2014). Looking at 337 
the effect of TPP concentration on particle size, it was demonstrated that the higher the concentration of 338 
TPP, the larger the particle size, this is because of the stiffening of the cross-linking bonds between TPP and 339 
CS associated with the rise of the tripolyphosphoric ions (Patel, Parikh, & Aboti, 2013). The increase in the 340 
drug concentration led to a decrease in the particle size, this could be attributed to the competition between 341 
PMZ and CS  cations to bind with TPP phosphoric ions which in turn will decrease the intermolecular cross 342 
linkage between CS and TPP and hence the formation of larger particles. Similar pattern was observed when 343 
higher concentration of acetic acid was used to solubilise CS; increasing the drug concentration will increase 344 
the  negative charge in the sample, which will interact with CS and promote the production of nanoparticles 345 
in the media.(Hong et al., 2014; Patel, Parikh, & Aboti, 2013; Luo, Zhang, Cheng, & Wang, 2010; Bugnicourt, 346 
Alcouffe, & Ladavière. 2014). On the other hand, stirring time does not show any effect on the particle size. 347 
Although it was reported in literature that stirring speed affected the particle size as the increase in the 348 
speed resulted in smaller particle size, this could be based on the increase in homogenization speed results 349 
in smaller particles (Hong,et al., 2014; Bugnicourt, Alcouffe, & Ladavière. 2014 ; Patel, Parikh, & Aboti, 2013).  350 
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3.1.2. The effect of different parameters on surface charge (zeta potential) 352 
The presence of glucosamine group on CS backbone contributes to the creation of positive charge on the 353 
surface of the polymer in acidic solutions. CS positively charged surface plays an important role in improving 354 
drug targeting and mucoadhesion properties. CS nanoparticles’ surface charge was affected by most of the 355 
variables, but it was clearly shown in the plot that the CS, TPP and drug concentration were the main factors 356 
influenced the change of surface charge (Fig 5& 6). 357 
 358 
Fig 5:- Main effects plot showing the influence of the independent variables on CS surface charge. 359 
14 
 
 360 
Fig 6:- Response surface plots of interaction effects between different variables and their effect on CS surface 361 
charge. Hold values are 0.20 for CS, 0.30 for TPP, 1.50 for CS:TPP, 60.00 for ST, 0.45 for DC and 0.30 for AA. 362 
The increase in CS concentration will be accompanied with an increase in protonized –NH3+ which increases 363 
the positive charge on the surface of the nanoparticles (Hong et al., 2014; Patel, Parikh, & Aboti, 2013; Luo, 364 
Zhang, Cheng, & Wang, 2010; Bugnicourt, Alcouffe, & Ladavière. 2014). Contrariwise, increasing TPP 365 
concentration will increase the interaction between CS and TPP and reduce the overall surface charge on the 366 
particles due to the presence of the negative charge on the surface.  In addition, the increase in the drug 367 
concentration resulted in a drop in zeta potential, which can be explained by the competition between CS 368 
and the drug to bind to TPP. Acetic acid did not have a significant effect (Fig 5), as it did not have a dramatic 369 
effect on the pH, all samples had a pH range of (pH 3.3-3.6). 370 
 371 
3.1.3. The effect of different parameters had on encapsulated efficiency 372 
   373 
The encapsulated efficiency was detected by measuring the amount of drug (PMZ) in the supernatant, after 374 
centrifugation of the nanoparticles. The current study looked at 2 concentrations of PMZ; 0.4mg/ml, 375 
0.8mg/ml and the results obtained indicated an EE range of (95-99%).  376 
The obtained results outlined that EE was significantly affected by the CS:TPP ratio and drug concentration 377 
(FigS 7&8). Increasing DC was associated with increasing the entrapment efficiency. Nonetheless, all the 378 
prepared formulations had entrapment efficiency greater than 95%. Previous studies had demonstrated that 379 
the nature of the drug -whether hydrophilic or hydrophobic- will not have an effect on the encapsulation 380 
efficiency (Cafaggi, et al., 2007; Bugnicourt, Alcouffe, & Ladavière. 2014; Klancke 2003). Moreover, the study 381 
conducted by Yan Wu et al., claimed that the drug concentration has no effect on the EE despite using 382 
similar concentration range (0.2-0.8mg/ml) to our study (Wu, Yang, Wang, Hu, & Fu, 2005) 383 
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There is a debate on the effect of CS concentration on EE of CS nanoparticles, previous studies conducted by 384 
Vandenberg et al., 2001 and Hassani 2014 reported that the increase in CS lead to the increase in drug 385 
encapsulation, mainly due to an increase in the CS concentration leading to an increase in the ion gelation 386 
hence better entrapment efficiency. In contrast a study by Wu et al. 2005 indicated that the increase of CS 387 
decreases the EE (Wu, Yang, Wang, Hu, & Fu, 2005). Nevertheless, our study demonstrated that CS 388 
concentration has no significant effect on PMZ entrapment (p<0.05). 389 
 390 
Fig 7:- Main effects plot showing the influence of the independent variables on the entrapment efficiency of 391 
PMZ 392 
 393 
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 394 
Fig 8:- Response surface plots of interaction effects between different variables and their effect on the 395 
entrapment efficiency of PMZ. Hold values are 0.20 for CS, 0.30 for TPP, 1.50 for CS:TPP, 60.00 for ST, 0.45 396 
for DC and 0.30 for AA. 397 
 398 
After identifying the effect variables on the responses, an optimization study was performed by Minitab 399 
(Table 2), to determine the optimum conditions to produce the nanoparticles with maximum drug loading 400 
and targeted particle size of 250 nm. Nanoparticles were prepared using the optimal conditions and 401 
evaluated to determine the accuracy of the conditions produced; the results obtained from the sample 402 
showed a particle size of 280nm, with EE of 99% and zeta potential of 20.8 mV.  Where Minitab  predicted a 403 
particle size of 250nm and EE of 94%, this can clearly conclude the precision of the optimization study by 404 
Minitab.  405 
Table 2:- Summary of the optimised conditions for preparing CS-nanoparticles 406 
 407 
3.2. Characterisation of coated CS nanoparticles 408 
The fast advances of polymeric sciences led to the introduction of a number of new polymers into the 409 
pharmaceutical industry and resulted into the production of a number of novel sustained release drug 410 
delivery systems. After optimisation of chitosan nanoparticles using the DOE approach, the optimised 411 
nanoparticulate system was coated with three polymers namely; PVP, PEG and PEAA which have cationic, 412 
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non-ionic and anionic nature, respectively. The nature of the coating polymer might affect the surface 413 
charge, particles size and loading capacity of chitosan nanoparticulate system.  Both PVP (Park 2003) and 414 
PEG (Park 2001) were co-grafted with chitosan to improve the low solubility of the hydrophobic polymer in 415 
aqueous solutions. The new grafted polymers were used for delivery of DNA molecules and showed 416 
responsiveness (Park 2001; Park 2003). The particles size for non-coated CS nanoparticles was not affected 417 
(p>0.05) by the incorporation of PMZ (Fig 9 and Table 3). Non-coated particles showed particle size of 418 
151.4±6.9 nm to 153.8±14.0 nm for non-coated PMZ nanoparticles and PMZ-free nanoparticles respectively. 419 
Nonetheless, incorporation of the coating polymers during the manufacturing of CS nanoparticles has 420 
affected both the particles size and surface charge (Fig 9). Addition of PVP was associated with an increase 421 
(p<0.05) in the particle size which reached 186±19 nm.  The cationic nature of PVP might be the reason of 422 
increasing the particle size of CS nanoparticles as the polymer might compete with chitosan to interact with 423 
TPP during the manufacturing process which will reduce the ionic gelation capacity of chitosan ,therefore 424 
larger particles were formed. On the other hand, addition of PEG decreased the size of the particles 425 
prepared (p<0.05). This can be explained by the ability of the electronegative oxygen atom of PEG to form 426 
intramolecular hydrogen bonding with the electropositive amino hydrogen on CS as reported by (Kim and 427 
Lee, 1995) which in turn tighten the nanoparticle structure, therefore a smaller size (124±5.2 nm; PDI 428 
0.32±0.04) was obtained. In a similar pattern, the surface charge on PEG-CS coated nanoparticles has 429 
decreased significantly (p<0.05) to 21.3±6.8 mV when compared to non-coated PMZ nanoparticles (31.4±0.9 430 
mV). Similar trend was reported by Wu et al (2005) and Quellec et al., (1998). PEAA is the third polymer used 431 
to coat CS nanoparticles. PEAA did not have any effect on the particle size (p>0.05) or the surface charge of 432 
the prepared nanoparticulate system (Fig 9). This could be attributed to the weak acidic nature of the 433 
polymer (pKa of 4.25) which has a minimal effect on the pH of CS acetic acid solution and hence minimal 434 
effect on the characteristics of the nanoparticles as suggested by (Wu, Yang, Wang, Hu, & Fu, 2005; 435 
Bugnicourt, Alcouffe, & Ladavière. 2014; Quellec et al., 1998).)  436 
Table 3:- Summary of particle size, surface charge, PDI and entrapment efficiency of coated and non-coated 437 
CS-nanoparticles (mean±SD) 438 
Sample particle size (nm) surface charge (mV)  PDI EE% 
PVP-coated nanoparticle  186±19.00 39.7±1.50 0.27±0.19 99.69±0.04   
PEAA-coated nanoparticle 153.8±5.40 28.6±6.60 0.47±0.10 99.74±0.00    
PEG-coated nanoparticle 124±5.20 21.3±6.80 0.32±0.04 99.77±0.06  
Non-coated PMZ nanoparticles  151.4±6.90 31.4±0.90 0.67±0.08 99.77±0.06 
PMZ-free nanoparticles  153.8±14.00 38.6±2.60 0.42±0.29  - 
18 
 
 439 
 440 
 441 
Fig 9:- Effect of coating polymers on the particle size and surface charge of CS nanoparticles. 442 
 443 
Encapsulation efficiencies (EE) of coated nanoparticles were evaluated as well (Fig 10). All coated 444 
nanoparticulate systems showed high percentage of EE ranged around (99.5%-99.9%), which suggest that 445 
different coating polymers did not affect the encapsulation efficiency of CS nanoparticles (p>0.05).  446 
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 448 
 449 
Fig 10:-Effect of coating polymers on the encapsulation efficiency of CS nanoparticles.  450 
3.3. Scanning electron microscopy (SEM) 451 
  452 
In order to investigate the morphology and surface properties of the prepared nanoparticles, SEM was used. 453 
(Fig11) shows SEM images of PMZ HCl, chitosan polymer, plain CS-nanoparticles, PEG-coated nanoparticles, 454 
PVP-coated nanoparticles, PEAA-coated nanoparticles  and non-coated CS nanoparticles. PMZ HCl showed 455 
cubic crystals with a wide range of particle size ranging from few µms to 200 µm. Small and large crystals 456 
aggregate together forming raspberry like aggregates (Fig11B). Chitosan particles were irregular in shape 457 
with some folds on their surface. CS particles showed large particle size greater than 400 µm (Fig 11C). All 458 
the prepared nanoparticles; coated and non-coated were spherical in shape and showed particles size in 459 
nano-range as suggested by DLS studies. Plain CS-nanoparticles showed a smooth surface without any 460 
evidence of aggregate formation; probably the high surface charge (ξ=38.6±2.6 mV) prevented any 461 
aggregation through electrostatic repulsion between the positively charge particles. Similarly, only few 462 
aggregates were observed when nanoparticles were coated with PVP (Fig11F). In contrary, loads of 463 
aggregates appeared under the microscope when PEAA was used as a coating polymer (Fig11G), this could 464 
be attributed to the anionic nature of PEAA which decreased the overall charge on the CS nanoparticles 465 
(ξ=28.6±6.6 mV). Similar trend was observed with PEG-coated nanoparticles (Fig 11E).  466 
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 493 
 494 
Fig 11:- SEM images of PMZ HCl at low magnification (A) and high magnification (B), chitosan polymer (C), plain CS-nanoparticles (D), 495 
PEG-coated nanoparticles (E), PVP-coated nanoparticles (F), PEAA-coated nanoparticles (G) and non-coated CS nanoparticles (H). 496 
 497 
 498 
3.4. Thermal analysis 499 
Differential scanning calorimeter is used to determine any change in the physic-chemical properties of the 500 
material by measuring the energy transfer from and to PMZ. Moreover, differential scanning calorimetry will 501 
enable investigation of any interaction between PMZ and CS or the coating polymers used in this study. 502 
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(Fig12) shows the rate of heat absorption for PMZ, CS, PEG-coated nanoparticles, PVP-coated nanoparticles, 503 
PEAA-coated nanoparticles and non-coated CS nanoparticles. DSC has shown a sharp endothermic peak at 504 
234 oC corresponding to the melting of PMZ HCl salt (Fig12A) (Lutka, A 2002; Ambrogi, Nocchetti, & Latterini, 505 
2014). Chitosan thermal scans has shown a broad endothermic peak between 60 and 140 oC and this is 506 
attributed to evaporation of water that is associated with the hydrophilic groups of CS (Figure 12 B). 507 
Coupling DSC scans with TGA can confirm this finding as a weight loss of (19 %) was observed between 60- 508 
140 oC (Fig13B). Similar findings were reported earlier by (Dong, Ruan, Wang, Zhao, & Bi, 2004; Mladenovska 509 
et al., 2007). PMZ-CS nanoparticles (Fig12F) did not show any endothermic or exothermic peaks and PMZ HCl 510 
endothermic peak disappeared which suggests possible interaction between the drug and CS by Van der 511 
Waals force within the nanoparticles.   Moreover, it was reported that spaces between CS chain provide 512 
favourable conditions for dispersing drug within CS nanoparticles (Sarmento, Ferreira, Veiga,  & Ribeiro, 513 
2006; Dos et al., 2011) 514 
 515 
Fig 12:- DSC scans of PMZ HCl salt (A), CS (B), PEG-coated nanoparticles (C), PVP-coated nanoparticles (D), PEAA-coated nanoparticles 516 
(E) and non-coated CS nanoparticles (F). 517 
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 518 
Fig 13:- TGA scans of PMZ HCl salt (A), PEAA-coated nanoparticles (B), non-coated CS nanoparticle (C), PVP-coated nanoparticles (D) 519 
PEG-coated CS nanoparticles (E) and non-coated CS nanoparticles (F). 520 
CS-coated nanoparticles showed similar scans to non-coated CS-nanoparticles as PMZ HCl endothermic peak 521 
disappeared because of the dispersion of the drug between CS and the coating polymer used. 522 
3.5. ODTs preparation and evaluation  523 
 524 
After preparation and characterisation of various CS-nanoparticles, the particles were incorporated into 525 
orally disintegrating tablet matrix  adapted from (ElShaer, A, Butt, U, Rauf, I , Sohaib Saboley, & Gawad, M 526 
2014) and based on the following formulation 25% LH-B1, 1% Magnesium stearate, 5% PMZ and 69% D (+)-527 
Lactose Monohydrate. After the preparation of ODTs, the tablets were then evaluated for their hardness, 528 
friability, disintegration time, dissolution profiles.  529 
3.5.1. Hardness, disintegration time and friability  530 
 531 
Hardness and friability tests were performed to determine if the tablets produced have a significant 532 
mechanical strength to stand fraction and erosion. The mechanical strength of ODTs is a critical parameter, 533 
as ODTs are prepared under low compression in order to form highly porous compress for fast 534 
disintegration. Nonetheless, the preparation process together with the excipients used might results in 535 
producing a friable/ brittle tablet. Control ODTs did not contain any nanoparticles within their matrix and 536 
showed fast disintegration time of 34±1.4 sec and high tensile strength of 2.7±0.25 N/mm2. Addition of 537 
A 
B 
C 
D 
E 
F 
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coated and non-coated CS nanoparticles into ODTs tablet matrix did not distort the characteristics of the 538 
tablets (Fig 14) and Table (4). All ODTs showed disintegration time between 25- 35 sec and tensile strength 539 
ranging from 2.5-3 N/mm2. All tablets showed no significant effect (p<0.05) in disintegration time comparing 540 
to each other (p>0.05) , but had a statistical significant affect comparing to the disintegration time of the 541 
control tablet(p<0.05). All the prepared tablets passed the friability test (Table 4) with highest friability of 542 
0.9% exhibited by ODTs containing PVP coated nanoparticles. 543 
 544 
Fig 14:- Tensile strength and disintegration time of ODTs containing non-coated CS-nanoparticles, PEAA coated CS-nanoparticles, PEG 545 
coated CS nanoparticles, PVP coated CS nanoparticles and control ODTs.  546 
Table 4:- Thickness, diameter (mean±SD) and friability of ODTs tablets containing coated and non-coated CS nanoparticles.  547 
sample Thickness (mm)  Diameter (mm) Friability (%) 
Control tablet  13.1±0.04 2.71±0.25 0.75% 
PEAA coated nanoparticle tablet 13.02±0.04 2.66±0.22 0.5% 
PEG coated nanoparticle tablet 13±0 2.56±0.30 0.7% 
PVP coated nanoparticle tablet 13.06±0.054 2.66±0.05 0.9% 
Non-coated nanoparticle tablet 13.04±0.054 2.68±0.04 0.6% 
 548 
3.5.2. Dissolution test  549 
 550 
In order to evaluate the release profile across CS-nanoparticles containing tablets, in vitro dissolution studies 551 
were performed.  Control tablets showed a fast release of PMZ as 46.1±0.3 % of the drug was released 552 
within 20 mins of the dissolution study and 97.3±0.13% was released at 60 mins. On the other hand, tablets 553 
containing CS-nanoparticles showed a slower release profile that became even slower upon coating the 554 
nanoparticles (Fig15). Non-coated chitosan nanoparticles managed to sustain the drug release for 24 hours 555 
with only 35.5±0.14% and 68.8±3.3% after 2 and 6 hours respectively. Similar release profiles were reported 556 
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by (Lu et al., 2009) when using CS nanoparticles to deliver aminoglycosides such as gentamicin and 557 
tobramycin. As more than 60% of the drugs were retained inside CS nanoparticles for 6 hours at pH of 1.2. 558 
Unmodified CS has been used intensively to sustain the drug release for several therapeutic agents such as 559 
ammonium glycyrrhizinate.( Wu, Yang, Wang, Hu, & Fu, 2005) dorzolamide hydrochloride, and pramipexole 560 
hydrochloride (Papadimitriou, Bikiaris, Avgoustakis, Karavas,  & Georgarakis, 2008) ciprofloxacin (Jain, & 561 
Banerjee,. 2008) and even for peptides and proteins ( Jiang, Pan, Cao, Jiang,  Hua, & Zhu, 2012). 562 
Nevertheless, CS-nanoparticles fail to sustain the drug release for longer time as the acidic conditions in the 563 
stomach solubilise chitosan (George, & Abraham, 2006). Therefore a second coating polymer was used in 564 
this study. The in vitro dissolution test indicated that coated nanoparticles had a slower release profile 565 
compared to non-coated, even after 24hr the drug release from the nanoparticle was not complete Fig (15).   566 
PEAA coated nanoparticles showed a burst effect as 45±0.9 % of PMZ was release within 2 hours of the 567 
dissolution study and the drug release remained below 58.6±0.23% during the time course of the 568 
experiment. Despite the weak acidic nature of PEAA which was believed to reduce its dissolution under the 569 
acidic conditions of this study (0.1N HCl), PEAA-CS particles exhibited a burst effect, possibly because some 570 
of PMZ was attached to the surface of the nanoparticles and released ring the first few hours of the 571 
dissolution study as suggested earlier by (Patel, Parikh, & Aboti, 2013). On the other hand, PVP and PEG 572 
coated nanoparticles showed the slowest amount of drug release over 24hr. PEG and PVP-coated CS 573 
nanoparticles released 13.86±0.13% and 7.6±0.54 % after 6 hours of the dissolution study respectively. And 574 
less than 45% of PMZ after 24 hours of the dissolution study. 575 
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 576 
Fig 15:- In vitro dissolution study of orally disintegrating tablets containing PMZ (control), non-coated CS NPs, PEAA-coated CS-NPs, 577 
PEG-coated CS-NPs and PVP-coated CS-NPs. 578 
3.5.2.3. Sulforhodamine B (SRB) cytotoxic assay.  579 
The SRB assay was used to study the cytotoxic effect of the prepared nanoparticles. Figure (16) illustrate the 580 
cell viability of Caco-2 cell lines after 24 hours incubation with different concentration of the nanoparticles 581 
compared to the negative control.  The average cell viability for the highest concentration (40 mg/mL) of the 582 
PVP coated nanoparticles was 85% (p<0.05) compared to the untreated cell (negative control), similar 583 
findings were suggested earlier by Lara et al (2010). Likewise, the cell viability of PEG coated nanoparticles 584 
were significantly (p<0.05) reduced  to 80%, this could be ascribed to the ability of PEG to form hydrogen 585 
bonding with surrounding water which in turn increases the osmotic pressure of the surrounding media. This 586 
osmotic shock will be associated with disorganisation of the nuclear chromatin cells of the Caco-2 cells by 587 
hyper-condensation of the nuclear chromatin and accumulation of cytoplasmic vesicles as suggested by 588 
Gilles et al., 1995 and Parnaud et al., 2001. On the other hand, lower concentrations of both PVP and PEG 589 
(20 mg/mL and 10 mg/mL) showed no signs of toxicity on the mammalian cells (Fig 16). In contract to PVP 590 
and PEG behaviors,  40 mg/mL of the chitosan and PEAA nanoparticles had no significant (p>0.05) effect on 591 
the cells’ viability. The average cell viability for the chitosan and PEAA coated nanoparticles were 92% and 592 
96% respectively. These results are in agreement with previous studies conducted by (Huang et al., 2004) 593 
suggesting that higher concentrations of CS is associated with cell toxicity because of the higher surface 594 
charge density which is a high contributor to cell death. Other concentration of the prepared nanoparticles 595 
had no significant effect on the Caco-2 cell lines after 24 hours incubation period (p>0.05) 596 
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 597 
Figure 16:-  SRB cytotoxic assay for the effect of chitosan and coated nanoparticles on Caco-2 cell line after 24 hours incubation. 598 
Results express as mean value ±SD (n=6), ***p<0.001, ****p<0.0001 599 
 600 
 Conclusion  601 
 602 
The properties of CS nanoparticles was engineered using Minitab in order to manufacture a new formulation 603 
of SR-ODTs. Minitab studies revealed that the nanoparticles’ particle size is affected by most of the 604 
independent variables. The concentration of TPP and CS was associated with an increase in the particles size 605 
and this is possibly due to  the stiffening of the cross linking bonds between TPP and CS, and the increase in 606 
the viscosity which will affect the shear capacity of homogenization leading to the formation of aggregates 607 
with large particle size, respectively. Drug concentration and CS:TPP ratios were the two main variables 608 
affecting the encapsulations efficiency. The engineered nanoparticles were further characterised using SEM 609 
which revealed that all the samples were spherical in shape with smooth surface and had particle size 610 
ranging between 100- 200 nm that goes in line with DLS results. Optimised CS-nanoparticles were further 611 
coated with polyvinylpyrolidine (PVP), polyethylene glycol (PEG) and polyethylene co-acrylic acid (PEAA). The 612 
coated nanoparticles were incorporated into ODTs. All tablets had passed the friability test and showed good 613 
tensile strength despite disintegrating in less than 40sec. The drug release profile was studied in 0.01M HCL 614 
solution showing that tablets containing PVP and PEG coated nanoparticles managed to sustain the drug 615 
release over 24hr, yet showed a slight toxic effect on Caca-2 cell lines at high concentrations of 40 mg/mL. 616 
On the other hand, non-coated and PEAA nanoparticles showed a faster rate of release without any 617 
pronounced effect on the viability of Caco-2 cells. 618 
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